SCHEMBL25899165

SCHEMBL25899165

CC(C)c1cnc2nc[nH]c(=O)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
HPGD P15428 5/20 0.49
XDH P47989 2/20 0.49
HSD17B10 Q99714 4/20 0.43
KDM4E B2RXH2 3/20 0.43
TSHR P16473 2/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
LMNA P02545 2/20 0.35
ADORA2A P29274 1/20 0.35
SLC6A4 P31645 1/20 0.35
ADRA1A P35348 1/20 0.35
BLM P54132 1/20 0.35
USP2 O75604 1/20 0.34
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14394570 0.80 HPGD (0.44) ALDH1A1HPGDXDHHSD17B10KDM4E
SCHEMBL24629159 0.77 ALDH1A1 (0.52) ALDH1A1HPGDXDHHSD17B10KDM4E
SCHEMBL14394573 0.76 ALDH1A1 (0.43) ALDH1A1HPGDXDHHSD17B10KDM4E
SCHEMBL18237721 0.75 KDM4E (0.40) ALDH1A1HPGDXDHHSD17B10KDM4E
SCHEMBL25899101 0.74 HSD17B10 (0.71) ALDH1A1HPGDHSD17B10KDM4ELMNA
SCHEMBL16333912 0.74 ALDH1A1 (0.49) ALDH1A1HPGDXDHHSD17B10KDM4E
SCHEMBL18237577 0.73 PARP1 (0.42) ALDH1A1HPGDHSD17B10KDM4ETSHR
SCHEMBL16984409 0.73 XDH (0.49) ALDH1A1HPGDXDHHSD17B10KDM4E
SCHEMBL12120593 0.72 KDM4E (0.40) ALDH1A1HPGDXDHHSD17B10KDM4E
SCHEMBL25899166 0.71 HSD17B10 (0.49) ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A ALDH1A1 4520/4885HPGD 4834/4885XDH 4457/4885
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, ASGR1, FCGR3B ALDH1A1 4368/4885HPGD 4872/4885XDH 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.